SCHEMBL19940307

SCHEMBL19940307

COC(=O)c1ccc(C(CCC2CCC2)n2ccc3cc(-c4ccc(C)cc4)ccc32)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCGR P47871 6/20 0.43
TDP1 Q9NUW8 1/20 0.36
CHRM4 P08173 1/20 0.35
EPHX2 P34913 1/20 0.35
MAPT P10636 2/20 0.35
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
LMNA P02545 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
NPC1 O15118 1/20 0.34
NFKB1 P19838 1/20 0.34
RAB9A P51151 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
ATM Q13315 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19923020 0.91 GCGR (0.54) GCGRTDP1ALDH1A1CYP3A4CYP2C19
SCHEMBL19940306 0.85 GCGR (0.63) GCGR
SCHEMBL19940303 0.83 GCGR (0.43) GCGRTDP1
SCHEMBL19922897 0.79 GCGR (0.55) GCGRADRB3
SCHEMBL19922880 0.76 GCGR (0.73) GCGR
SCHEMBL19923021 0.74 GCGR (0.55) GCGRALDH1A1CYP3A4CYP2C19
SCHEMBL19940302 0.72 GCGR (0.45) GCGRMAPTALDH1A1
SCHEMBL19940299 0.69 GCGR (0.70) GCGR
SCHEMBL19970036 0.69 HRH3 (0.41) GCGR
SCHEMBL19922872 0.68 MAPT (0.42) TDP1EPHX2MAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10251864-B2 Indole derivatives useful as glucagon receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2019-04-09 US disclosed
US-20180064686-A1 INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2018-03-08 US disclosed
US-20180064686-A1 INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2018-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10251864-B2 Indole derivatives useful as glucagon receptor antagonists GPR119, GIPR, GLP1R GCGR 4/4885TDP1 4494/4885CHRM4 898/4885
US-20180064686-A1 INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS GPR119, GIPR, GLP1R GCGR 4/4885TDP1 4494/4885CHRM4 898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.